Often called "the itch that rashes," atopic dermatitis symptoms typically include patches of red, dry, inflamed skin, the AAD says. "Atopic dermatitis is really just inflamed skin or skin that's ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a ...

seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic, debilitating and relapsing skin disease. With the FDA granting a priority review status to the sBLA, a decision is ...